This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wagner, F. D. Articles by Hocher, B. Search for Related Content PubMed PubMed Citation Articles by Wagner, F. D. Articles by Hocher, B.

(Circulation. 2003;108:II-278.)
© 2003 American Heart Association, Inc.

Mechanical Circulatory Support

Modulation of Circulating Endothelin-1 and Big Endothelin by Nitric Oxide Inhalation Following Left Ventricular Assist Device Implantation

Frank D. Wagner, MD, PhD; Semih Buz, MD; Christoph Knosalla, MD, PhD; Roland Hetzer, MD, PhD; Berthold Hocher, MD, PhD

From the Deutsches Herzzentrum Berlin, Germany Charité der Humboldt Universität Berlin, Berlin, Germany.

Correspondence to Dr Frank Wagner Deutsches Herzzentrum Berlin Augustenburger Platz 1 13353 Berlin, Germany. Phone: 30-4593-2111; Fax 30-4593-1852; E-mail Wagner{at}dhzb.de

Background— Inhaled nitric oxide (iNO) is an established therapy in the treatment of pulmonary hypertension and right ventricular dysfunction following left ventricular assist device implantation. Since it is known that endothelin-1 contributes to pulmonary hypertension, and nitric oxide modulates endothelin-1 synthesis in vitro, we investigated the effects of iNO on circulating endothelin-1 and big endothelin following left ventricular assist device implantation.

Methods and Results— On weaning from cardiopulmonary bypass, 15 consecutive patients with secondary pulmonary hypertension after implantation of a left ventricular assist device were treated with iNO. Endothelin-1 and big endothelin plasma levels were measured preoperatively, on cardiopulmonary bypass prior to iNO, 12, 24, and 48 hour postoperatively, and 72 hour after cessation of iNO. Endothelin-1 levels were increased preoperatively (1.05±0.20 fmol/L), and were highest on cardiopulmonary bypass (1.65±0.27 fmol/L). During iNO therapy endothelin-1 and big endothelin decreased significantly (endothelin-1: 12 hour 1.24±0.18, 24 hour 0.93±0.20, and 48 hour 0.81±0.14 fmol/L); they were lowest 72 hour post-iNO (endothelin-1: 0.56±0.09 fmol/L). Plasma endothelin-1 concentrations and iNO dose were inversely correlated (r=-0.657, P<0.015). A significant correlation was also found between endothelin-1 versus PA pressures and PVR/SVR ratio, but not with CI and SVR.

Conclusions— Since it is known that endothelin-1 mediates pulmonary hypertension, we suggest a 2-fold effect of iNO therapy: firstly, a selective vasodilation of the pulmonary vasculature; and secondly, iNO mediated modulation of endothelin-1.

Key Words: nitric oxide • endothelin • heart-assist device